Brief: Ideaya Biosciences Announces Ind Submission For Ide574
10/12/2025 11:02
Dec 10 (Reuters) - IDEAYA Biosciences Inc IDYA.O: IDEAYA BIOSCIENCES ANNOUNCES IND SUBMISSION FOR IDE574, A POTENTIAL FIRST-IN-CLASS KAT6/7 DUAL INHIBITOR FOR BREAST AND LUNG CANCERS IDEAYA BIOSCIENCES- PHASE 1 DOSE ESCALATION TRIAL OF MONOTHERAPY IDE574 EXPECTED TO BEGIN IN 1Q 2026 IDEAYA BIOSCIENCES INC - PRECLINICAL DATA FOR IDE574 TO BE PRESENTED IN 1H 2026 Source text: ID:nPn2rxmDsa Further company coverage: IDYA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on IDEAYA Biosciences
See all newsBrief: Ideaya Biosciences And Servier Announce Data From Three Clinical Trials At Esmo 2026 Supporting The Potential Of Darovasertib To Become A Foundational New Therapy For Patients Across The Treatment Journey Of Uveal Melanoma
Brief: Ideaya Biosciences Announces The Promotion Of Dr. Michael White To President, Research And Development
Brief: Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Ideaya Biosciences Inc Reports Results For The Quarter Ended June 30: Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj